# US 2016/0251380 A1 · Tricyclic benzoxaborole compounds and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0251380 A1
- Document ID: US20160251380A1
- Status: Published application
- Kind: A1
- Application number: 14/387,384
- Filed: 2014-08-08
- Published: 2016-09-01
- Earliest claimed: 2013-08-09
- Assignees: Glaxosmithkline Intellectual Property (No.2) Limited; Anacor Pharmaceuticals, Inc.
- Applicants: Glaxosmithkline Intellectual Property (No.2) Limited; Anacor Pharmaceuticals, Inc.
- Inventors: M.R.K. (DICKON) ALLEY; VINCENT S. HERNANDEZ; JACOB PLATTNER; XIANFENG LI; DAVID BARROS-AGUIRRE; ILARIA GIORDANO
- Web page: https://patentgrep.com/patent/US20160251380A1

## CPC

- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- C07F 5/04: Esters of boric acids
- A61K 31/69: Boron compounds
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 31/04: Antibacterial agents
- A61P 31/06: for tuberculosis
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07F 5/025: {Boronic and borinic acid compounds}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Compounds of Formula II, wherein X is selected from chloro, fluoro, bromo and iodo, R1 and R2 are each independently selected from H, —CH3, —CH2CH3, —CH2CH2CH3, or —CH(CH3)2; compositions containing them, their use in therapy, including their use as anti-mycobacterial agents, for example in the treatment of a mycobacterial infection in a mammal, and methods for the preparation of such compounds, are provided.

## Claims

### Claim 1

A compound having a structure as shown in Formula II:
wherein X is selected from fluoro, chloro, bromo or iodo and R1 and R2 are each independently selected from H, —CH3, —CH2CH3, —CH2CH2CH3, and —CH(CH3)2; or a salt thereof.

### Claim 2 (depends on 1)

A compound according to claim 1 or a salt thereof, wherein X is chloro or bromo.

### Claim 3 (depends on 1)

A compound according to claim 1, or a salt thereof, which is

### Claim 4 (depends on 3)

A compound according to claim 3, which is

### Claim 5 (depends on 3)

A compound according to claim 3 which is:

### Claim 6 (depends on 1)

A compound according to claim 1 which is:

### Claim 7 (depends on 1)

A compound according to claim 1 which is:

### Claim 8

A compound having a structure as shown in Formula IIa:
wherein X is fluoro, chloro, bromo or iodo, and R1 and R2 are each independently selected from H, —CH3, —CH2CH3, —CH2CH2CH3, and —CH(CH3)2, or a salt thereof.

### Claim 9 (depends on 8)

A compound according to claim 8, or a salt thereof, which is

### Claim 10 (depends on 8)

A compound according to claim 8 which is

### Claim 11 (depends on 8)

A compound according to claim 8 which is

### Claim 12 (depends on 8)

A compound according to claim 8 which is

### Claim 13 (depends on 8)

A compound according to claim 8 which is

### Claim 14

A compound, (S)-(3-bromo-7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen-2-yl)methanamine, having the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 15

A compound, (S)-(3-chloro-7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen-2-yl)methanamine, having the formula:

### Claim 16

A compound, (S)-(3-chloro-7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen-2-yl)methanamine, having the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 17

A pharmaceutically acceptable salt of a compound, (S)-(3-chloro-7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen-2-yl)methanamine, having the formula:

### Claim 18

A pharmaceutical composition comprising a compound, (S)-(3-chloro-7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen-2-yl)methanamine, having the formula:
together with at least one pharmaceutically acceptable excipient.

### Claim 19

A compound, (S)-(3-bromo-8,8-dimethyl-7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen-2-yl)methanamine, having the formula:

### Claim 20

A compound, (S)-(3-bromo-8,8-dimethyl-7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen-2-yl)methanamine, having the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 21

A pharmaceutically acceptable salt of a compound, (S)-(3-bromo-8,8-dimethyl-7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen-2-yl)methanamine, having the formula:

### Claim 22

A pharmaceutical composition comprising a compound, (S)-(3-bromo-8,8-dimethyl-7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen-2-yl)methanamine, having the formula:
together with at least one pharmaceutically acceptable excipient.

### Claim 23

A compound selected from the group consisting of:
(3-bromo-7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen-2-yl)methanamine;
(S)-(3-bromo-7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen-2-yl)methanamine;
(3-chloro-7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen-2-yl)methanamine;
(S)-(3-chloro-7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen-2-yl)methanamine;
(3-chloro-8-methyl-7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen-2-yl)methanamine;
(3-bromo-8-methyl-7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen-2-yl)methanamine;
(3-bromo-8,8-dimethyl-7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen-2-yl)methanamine;
(S)-(3-bromo-8,8-dimethyl-7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen-2-yl)methanamine;
(3-chloro-8,8-dimethyl-7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen-2-yl)methanamine;
(S)-(3-chloro-8,8-dimethyl-7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen-2-yl)methanamine;
(3-fluoro-7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen-2-yl)methanamine; and
(S)-(3-iodo-7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen-2-yl)methanamine,
or a pharmaceutically acceptable salt thereof.

### Claim 24 (depends on 1, 8, 23)

A compound according to any of claim 1, 8 or 23 wherein the pharmaceutically acceptable salt is selected from a hydrochloride, a hydrobromide, a hydriodide, a nitride, a carbonate, a monohydrogencarbonate, a phosphate, a monohydrogenphosphate, a dihydrogenphosphate, a sulfate, a monohydrogensulfate, a dihydrogensulfate, or a phosphonate salt.

### Claim 25 (depends on 1, 8, 23)

A compound according to claim 1, 8 or 23, wherein the pharmaceutically acceptable salt is an acetate, a propionate, an isobutyrate, a maleate, a malonate, a benzoate, a succinate, a suberate, a fumarate, a glucaronate, a galacturonate, a lactate, a mandelate, a phthalate, a benzenesulfonate, a p-tolylsulfonate, a citrate, a tartrate, or a methanesulfonate salt.

### Claim 26 (depends on 1, 8, 23)

A compound according to any of claim 1, 8 or 23, wherein the pharmaceutically acceptable salt is a salt of an amino acid including an arginate or a lysinate salt.

### Claim 27 (depends on 24)

A compound according to claim 24 wherein the pharmaceutically acceptable salt is a hydrochloride salt or a dihydrogensulfate salt.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A combination comprising:
a first therapeutic agent, which is a compound of Formula II or Formula IIa, or a pharmaceutically acceptable salt thereof, according to any of claims 1 through 27;
optionally a second therapeutic agent;
optionally a third therapeutic agent;
optionally a fourth therapeutic agent;
optionally a fifth therapeutic agent; and
optionally a sixth therapeutic agent,
wherein the optional second, third, fourth, fifth, or sixth therapeutic agent is not a compound of Formula II or Formula IIa.

### Claim 29 (depends on 27)

A combination according to claim 27, wherein the optional second, third, fourth, fifth and sixth therapeutic agent is independently selected from isoniazid, rifampin, pyrazinamide, ethambutol, moxifloxacin, rifapentine, clofazimine, bedaquiline (TMC207), nitroimidazo-oxazine PA-824, delamanid (OPC-67683), an oxazolidinone, EMB analogue SQ109, a benzothiazinone, a dinitrobenzamide and an antiviral agent including an antiretroviral agent.

### Claim 30 (depends on 27)

A combination according to claim 27, wherein the oxazolidinone is linezolid, tedizolid, radezolid, sutezolid (PNU-100480), or posizolid (AZD-5847).

### Claim 31 (depends on 27)

A combination according to claim 27, wherein the optional second, third, fourth, fifth and sixth therapeutic agent is selected from a therapeutic agent approved or recommended for the treatment of tuberculosis.

### Claim 32 (depends on 27)

A combination according to claim 27, wherein the antiretroviral agent is zidovudine, didanosine, lamivudine, zalcitabine, abacavir, stavudine, adefovir, adefovir dipivoxil, fozivudine, todoxil, emtricitabine, alovudine, amdoxovir, elvucitabine, nevirapine, delavirdine, efavirenz, loviride, immunocal, oltipraz, capravirine, lersivirine, GSK2248761, TMC-278, TMC-125, etravirine, saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, brecanavir, darunavir, atazanavir, tipranavir, palinavir, lasinavir, enfuvirtide, T-20, T-1249, PRO-542, PRO-140, TNX-355, BMS-806, BMS-663068 and BMS-626529, 5-Helix, raltegravir, elvitegravir, GSK1349572, GSK1265744, vicriviroc (Sch-C), Sch-D, TAK779, maraviroc, TAK449, didanosine, tenofovir, lopinavir, or darunavir.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

A pharmaceutical formulation comprising a first therapeutic agent, said first therapeutic agent being a therapeutically effective amount of a compound of Formula II or Formula IIa, or a pharmaceutically acceptable salt thereof, according to any of claims 1-27; or a combination according to any of claims 28-32, and a pharmaceutically acceptable excipient, adjuvant or diluent.

### Claim 34 (depends on 33)

A pharmaceutical formulation according to claim 33, further comprising a second therapeutic agent.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A method of killing a mycobacteria and/or inhibiting the replication of mycobacteria that cause disease in an animal, comprising contacting mycobacterial or an animal infected with mycobacteria with a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof according to any of claims 1-25, so as to kill the mycobacteria and/or prevent the replication of the mycobacteria.

### Claim 36 (depends on 35)

A method according to claim 35, wherein the mycobacteria is Mycobacterium tuberculosis.

### Claim 37 (depends on 35)

A method according to claim 35, wherein the disease is tuberculosis.

### Claim 38 (depends on 35)

A method according to claim 35, wherein the animal is a human.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 32, 33, 34, 35, 333)

A method of treating a mycobacterial infection in an animal comprising: administering to the animal any one of: (i) a therapeutically effective amount of a compound of Formula II or Formula IIa, or a pharmaceutically acceptable salt thereof, according to any of claims 1-27; (ii) a therapeutically effective amount of a combination according to any of claims 32-35; or (iii) a therapeutically effective amount of a pharmaceutical formulation according to any of claims 333-34, so as to treat the mycobacterial infection in the animal.

### Claim 40 (depends on 39)

A method according to claim 39, wherein the mycobacterial infection is an infection of a mycobacterium selected from Mycobacterium tuberculosis, Mycobacterium avium including subspecies (subsp.) Mycobacterium avium subsp. avium, Mycobacterium avium subsp. hominissuis, Mycobacterium avium subsp. silvaticum, and Mycobacterium avium subsp. paratuberculosis; Mycobacterium kansasii, Mycobacterium malmoense, Mycobacterium simiae, Mycobacterium szulgai, Mycobacterium xenopi, Mycobacterium scrofulaceum, Mycobacterium abscessus, Mycobacterium chelonae, Mycobacterium haemophilum, Mycobacterium leprae, Mycobacterium marinum, Mycobacterium fortuitum, Mycobacterium parafortuitum, Mycobacterium gordonae, Mycobacterium vaccae, Mycobacterium bovis, Mycobacterium bovis BCG, Mycobacterium africanum, Mycobacterium canetti, Mycobacterium caprae, Mycobacterium microti, Mycobacterium pinnipedi, Mycobacterium leprae, Mycobacterium ulcerans, Mycobacterium intracellulare, Mycobacterium tuberculosis complex. (MTC), Mycobacterium avium complex (MAC), Mycobacterium avian-intracellulare complex (MAIC), Mycobacterium gordonae clade; Mycobacterium kansasii clade; Mycobacterium chelonae clade; Mycobacterium fortuitum clade; Mycobacterium parafortuitum clade; and Mycobacterium vaccae clade.

### Claim 41 (depends on 39)

A method according to claim 39, wherein the mycobacteria is Mycobacterium tuberculosis.

### Claim 42 (depends on 39)

A method according to claim 39, wherein the disease is tuberculosis.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A compound of Formula II or Formula IIa according to any of claims 1-27, or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease resulting from a mycobacterial infection in an animal.

### Claim 44 (depends on 43)

A compound according to claim 43, wherein the mycobacterial infection is a Mycobacterium tuberculosis infection.

### Claim 45 (depends on 43)

A compound according to claim 43, wherein the disease is selected from tuberculosis, leprosy, Johne's disease, Buruli or Bairnsdale ulcer, Crohn's disease, pulmonary disease or pulmonary infection. pneumonia, bursa, synovial, tendon sheaths, localized abscess, lymphadenitis, skin and soft tissue infections Lady Windermere syndrome, MAC lung disease, disseminated Mycobacterium avium complex (DMAC), disseminated Mycobacterium avium intraceullulare complex (DMAIC), hot-tub lung, MAC mastitis, MAC pyomyositis, Mycobacterium avum paratuberculosis, or granuloma disease.

### Claim 46 (depends on 45)

A compound according to claim 45, wherein the disease is tuberculosis.

### Claim 47 (depends on 43)

A compound according to claim 43, wherein the animal is a human.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A use of a compound of Formula II or Formula IIa according to any of claims 1-27, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a mycobacterial infection in an animal.

### Claim 49 (depends on 48)

The use of claim 48, wherein the mycobacterial infection is a Mycobacterium tuberculosis infection.

### Claim 50 (depends on 49)

The use of claim 49 wherein the animal is a human.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A method of treating a disease resulting from a mycobacterial infection a mammal, which method comprises administering to the animal in need of such treatment an effective amount of a compound of Formula II or Formula IIa according to any of claims 1-27, or a pharmaceutically acceptable salt thereof.

### Claim 52 (depends on 51)

A method of treating a disease according to claim 51, wherein the mammal is a human.

### Claim 53 (depends on 51)

A method according to claim 51, wherein the mycobacterial infection is a Mycobacterium tuberculosis infection.

### Claim 54 (depends on 4951)

A method according to claim 4951 wherein the disease is selected from tuberculosis, leprosy, Johne's disease, Buruli or Bairnsdale ulcer, Crohn's disease, pulmonary disease or pulmonary infection. pneumonia, bursa, synovial, tendon sheaths, localized abscess, lymphadenitis, skin and soft tissue infections Lady Windermere syndrome, MAC lung disease, disseminated Mycobacterium avium complex (DMAC), disseminated Mycobacterium avium intracellulare complex (DMAIC), hot-tub lung, MAC mastitis, MAC pyomyositis, Mycobacterium avum paratuberculosis, or granuloma disease.

### Claim 55 (depends on 51)

A method according to claim 51, wherein the disease is tuberculosis.

### Claim 56 (depends on 51)

A method according to claim 51, wherein the animal is a human.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A method of treating a mycobacterial infection in an animal, particularly in a mammal, which method comprises administering to the animal in need of such treatment an effective amount of a compound according to any of claims 1-27, or a pharmaceutically acceptable salt thereof.

### Claim 58 (depends on 57)

A method according to claim 57, wherein the mycobacterial infection is a Mycobacterium tuberculosis infection.

### Claim 59 (depends on 57)

A method according to claim 57, wherein the animal is a human.
